Kombinierte Analyse von Paraoxonase-1- und IGF-2-Polymorphismen bei polyzystischem Ovarsyndrom

Abstract

This investigation indicates, that only the combined analyses of putative candidate genes allowed a genotype-phenotype correlation in PCOS.

PON1‐108 TT and PON1‐192 RR genotypes are more frequently encountered in Greek PCOS than non‐PCOS women, and are associated with hyperandrogenaemia

“…Knebel et al . reported comparable data for the PON1‐108 polymorphism in a PCOS population and controls (PCOS vs Control, CC: 26·79% vs 20·32%; CT: 47·68% vs 62·8%; TT: 25·8% vs 16·9%) . Other authors do not report any association of PON1‐108 genotypes or alleles with PCOS .…”

“…Other authors do not report any association of PON1‐108 genotypes or alleles with PCOS . In this study, comparable C and T allelic frequencies of the PON1‐108 polymorphism were found between the two studied groups, confirming the findings by Knebel et al . Furthermore, Brophy et al .…”

“…Reduced PON1 activity has been found in conditions associated with insulin resistance such as T2DM, cardiovascular atherosclerotic disease and PCOS . Also certain PON1 polymorphisms have been associated with PCOS . The PON1 gene consists of 9 exons spanning 26 kb, located in the 7q21·3 chromosome .…”

Association Between Single Nucleotide Polymorphisms of Sterol Regulatory Element Binding Protein-2 and Liver X Receptor α Gene and Risk of Polycystic Ovary Syndrome in a Chinese Han Population

“…The observed genotype frequencies were in Hardy-Weinberg equilibrium. Contingency tables, v 2 test (null hypothesis), Fisher's exact test, or Cochran-Armitage trend-tests were used to evaluate the differences in allele and genotype frequencies, as previously described [23]. The prevalence of the pathophysiological data was compared by 2-way ANOVA calculated with Prism 4.03 (GraphPad Software Inc., San Diego) or two-sided t test as indicated.…”

“…Diagnosis criteria of PCOS and a family history of metabolic diseases were excluded in the control group. Both PCOS patients and controls received no medications that have effect on glucose metabolism or endocrine parameters for at least 3 months before the entry of the study [22,23]. The Ethics committee at the Integrated Chinese and Western Medicine Hospital of Zhejiang Province approved the study protocol, and written informed consents were obtained from all participants.…”